BDNF, Cathepsin D, MPO, NCAM, PAI-1 (total), PDGF-AA, PDGF-AB/BB, RANTES, sICAM-1, sVCAM-1
$21.95 / sample (single analysis)
Serum & Plasma: 25μL for single, duplicate, and triplicate analysis.
Other sample types: 50μL single analysis. 75μL duplicate analysis. 100μL triplicate analysis.
Biomarker Research Areas:
Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, epilepsy, neurodegeneration, memory, cancer (Cathepsin D). coronary artery disease (MPO), fibrinolysis & MMP inhibition (PAI-1), angiogenesis (PDGFs), cellular adhesion.
Multiplex Assay Overview:
The assay service provided by Eve Technologies on their Human Supplemental Biomarker Array facilitates research in various categories such as neurodegenerative diseases, angiogenesis, and cellular adhesion. This Discovery Assay® measures ten biomarkers simultaneously in a single microwell: BDNF, Cathepsin D, MPO, NCAM, PAI-1 (total), PDGF-AA, PDGF-AB/BB, RANTES, sICAM-1, sVCAM-1.
This multiplex assay is supplemental for the Human Angiogenesis Array and the Human Cytokine Discovery Assays as it includes PDGFs and RANTES that are tested in the appropriate dilution for human serum / plasma. It can also supplement the MMP Discovery Assays as it includes PAI-1 which acts as an inhibitor to MMPs. Note that any of these ten analytes can be assayed in a custom-plex. Many of these analytes are available in other panels multiplexed with related analytes.
The assay is designed for protein analysis in serum, plasma, CSF, and cell cultures. Other sample types can be tested.
Human Supplemental Biomarker Array is offered as a Discovery Assay to supplement other Discovery Assays with targets of interest in optimal assay conditions. All of these biomarkers are in high concentration in human serum and plasma. Therefore, they are multiplexed together and run with a 1:100 serum/plasma dilution. The Supplemental Biomarker Array originates from a neurodegenerative multiplex panel:
Neurodegenerative disease is a condition characterized by the deterioration of neurons or their myelin sheath over time in the brain and/or spinal cord. These neurons are responsible for processing sensory information, making decisions, and controlling movement. Because these cells are not easily regenerated, excessive cumulative damage can lead to age-related diseases such as Alzheimer’s and Parkinson’s disease, as well as other conditions such as amyotrophic lateral sclerosis (ALS) and epilepsy. These disorders are devastating and expensive, both on a personal and global level, and as population demographics continue to change, a therapeutic solution is critical. Consequently, research is underway to identify biomarkers that will help scientists not only understand the pathogenesis of neurodegenerative disease, but also identify people with these disorders before the onset of symptoms and potentially provide new therapeutic tools.
Therefore, understanding neurobiology is fundamental to determining the pathogenesis of these devastating neurodegenerative diseases. Identification of key biomarkers and their accurate measurement is crucial. This Supplemental Biomarker Array along with other Neurodegenerative Panels available in our custom-plex menu allows you to explore complexities of the nervous system and the pathobiology of disease.
Intended Sample Type:
Human serum or plasma (EDTA recommended), CSF, cell cultures, tissue homogenates and others. Due to a wide range of sample conditions, a pilot run is recommended for cell cultures, tissue homogenates, and other sample types not listed.
Special Sample Preparation:
Serum and Plasma samples will be diluted 1:100 by Eve Tech to bring protein concentrations within the standard curve range.
Unless otherwise stated our products and services are intended for research use only.
Multiplex Immunoassay analyzed with a BioPlex 200
Biomarker Array Assay Kit Source:
Sensitivity, Variation, & Accuracy*Note: %CV is an appropriate measure of quality only for sample that have significant detectable concentrations for a particular analyte. Low concentration / low signal samples can often have a much higher %CV as the signals are at the limitations of the assay and fall within a flat portion of the curve.
% recovery is comparing the observed concentration to the expected concentration of samples spiked with the standard curve cocktail at various concentrations.